HPV genotypes in invasive cervical cancer in Danish women

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 9, 2013, Pages 1023-1031

  Kirschner, Benny ^a   Junge, Jette ^a   Holl, Katsiaryna ^b   Rosenlund, Mats ^b,c   Collas De Souza, Sabrina ^d   Quint, Wim ^e   Molijn, Anco ^e   Jenkins, David ^e   Schledermann, Doris ^f  

^a HVIDOVRE HOSPITAL   (Denmark)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c KAROLINSKA INSTITUTE   (Sweden)

^d 4Clinics ^*  (France)

^e DDL DIAGNOSTIC LABORATORY   (Netherlands)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cervical cancer; human papillomavirus; oncology; screening; vaccination

Indexed keywords

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DENMARK; ENDOMETRIUM CARCINOMA; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; TUMOR INVASION; UTERINE CERVIX CANCER; WART VIRUS;

CERVICAL CANCER; HUMAN PAPILLOMAVIRUS; ONCOLOGY; SCREENING; VACCINATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; DENMARK; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 84882453366     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12197     Document Type: Article

References (20)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-917.
2. Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer. 2009; 45: 1042-66.
3. Engholm G, Ferlay J, Christensen N, Johannesen TB, Klint Å, Køtlum JE, et al. NORDCAN: cancer incidence, mortality; prevalence and survival in the Nordic Countries. Copenhagen, Denmark: Association of the Nordic Cancer Registries. Danish Cancer Society, 2012.
4. National Board of Health. Nye tal fra Sundhedsstyrelsen. Sygehusbaseret Overlevelse for Udvalgte Kræftsygdomme 1994-2005. [New figures from the Health Protection Agency. hospital-based survival for selected cancer]. In Danish. Copenhagen: Danish National Board of Health, 2007. Report No. 5.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-9.
6. Schiffman M, Castle PE,. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003; 127: 930-4.
7. Lizano M, Berumen J, Garcia-Carranca A,. HPV-related carcinogenesis: basic concepts, viral types and variants. Arch Med Res. 2009; 40: 428-34.
8. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796-802.
9. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013; 132: 854-67.
10. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998; 153: 1731-9.
11. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17: 857-72.
12. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121: 621-32.
13. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-55.
14. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B,. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006; 44: 3292-8.
15. Morris BJ,. Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. Clin Chem Lab Med. 2005; 43: 1171-7.
16. Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, et al. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol. 2008; 111: 847-56.
17. Pirog EC, Kleter B, Olgac S, Bobkiewicz P, Lindeman J, Quint WG, et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol. 2000; 157: 1055-62.
18. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T,. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer. 2008; 123: 1864-70.
19. Clifford GM, Smith JS, Aguado T, Franceschi S,. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003; 89: 101-5.
20. Kirschner B, Poll S, Rygaard C, Wahlin A, Junge J,. Screening history in women with cervical cancer in a Danish population-based screening program. Gynecol Oncol. 2011; 120: 68-72.